BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

“The CHMP’s positive opinion of our new tablet formulation of BRUKINSA is an important step toward bringing this thoughtful, patient-centered innovation to people facing certain B-cell cancers ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

The enhanced service offering positions Superior Supplement Manufacturing as a leading partner for brands seeking reliable pet soft chew manufacturers support. The company has expanded its pet ...

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

First p articipants with obesity or o verweight w ith at least one w eight- r elated c omorbidity have been d osed in a U.

Here’s how a drug gets from an idea into patients’ hands – and why Australians sometimes wait longer to access a new drug ...

UniSA PhD candidate Deepa Nakmode and Professor Sanjay Garg in the lab.A new weekly injectable drug could transform the lives ...

Starton Therapeutics Inc., a clinical-stage biotechnology company, has entered into a collaboration agreement with Bend ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...

In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally ...